juvenile idiopathic arthritis


Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland

Annals of the Rheumatic Diseases. 2013;71:258-259


Hallinen T, Soini EJ, Diamantopoulos A, Dejonckheere F, Vihervaara V, Hautala A, Aalto K



A probabilistic Markov model was developed to evaluate cost-effectiveness of two treatment sequences from the Finnish healthcare payer perspective


Efficacy estimates were based on the results of a pivotal trial and adjusted indirect comparison of trials selected based on a systematic literature review which were both conducted by Symmetron (see Diamantopoulos et al., 2013)

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke


Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review


The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK


Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective